Literature DB >> 8575484

Gastrointestinal activity following bone marrow scintigraphy with technetium-99m nanocolloid in patients with multiple myeloma.

B Agren1, K Måre, P Aspelin.   

Abstract

Unexpected abdominal activity was registered later than 1 h post injection in technetium-99m bone marrow scintigrams of 13 multiple myeloma patients and of five controls. The activity was considered to be localised in the gastro-intestinal tract. It is attributed to accumulation of degradation products of the used nanocolloid tracer. Corresponding results are known in patients with inflammatory bowel disease when scintigraphy is performed with other radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575484     DOI: 10.1007/bf00801620

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  5 in total

1.  99Tcm-nanocolloid imaging in inflammatory bowel disease.

Authors:  J G Wheeler; N F Slack; A Duncan; M Palmer; R F Harvey
Journal:  Nucl Med Commun       Date:  1990-02       Impact factor: 1.690

2.  Clinical comparison of 99Tcm-HMPAO labelled leucocytes and 99Tcm-nanocolloid in the detection of inflammation.

Authors:  M Vorne; T Lantto; S Paakkinen; S Salo; I Soini
Journal:  Acta Radiol       Date:  1989 Nov-Dec       Impact factor: 1.990

3.  [Results of bone marrow scintigraphy in hematological diseases].

Authors:  G Ranner; G F Fueger; M Hörmann
Journal:  Rofo       Date:  1987-03

4.  Effect of size fractionation on the distribution of an albumin colloid in the reticuloendothelial system of the mouse.

Authors:  B Kalin; P Sellin; S Von Krusenstierna; P O Schnell; H Jacobsson
Journal:  Int J Rad Appl Instrum B       Date:  1991

5.  Technetium-99m nanocolloid for the scintigraphic assessment of inflammatory bowel disease in the colon: its value in comparison with indium-111-labelled granulocytes.

Authors:  J W Arndt; A van der Sluys Veer; D Blok; G Griffioen; H W Verspaget; A S Peña; C B Lamers; E K Pauwels
Journal:  Eur J Radiol       Date:  1991 Jan-Feb       Impact factor: 3.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.